Sanofi looks to set date for showdown with Medivation shareholders
pharmafile | June 2, 2016 | News story | Sales and Marketing | Medivation, Sanofi, hostile, record date, shareholders, takeover
Sanofi (NYSE: SNY) has announced that it has attempted to fix a record date with Medivation (NASDAQ: MDVN) where the shareholders at the company can decide whether or not to remove and replace the board in favour of members hand-picked by the French pharma company.
Sanofi has escalated their attempts to acquire the California-based oncology-focused company in recent weeks, amid growing reported interested from others, including Pfizer and Amgen. With the Medivation board having branded their $9.3 billion bid as “significantly undervaluing” the company, and apparently refusing to engage any further, Sanofi recently announced plans to replace the entire board at the company.
If the shareholders decide to elect a new board, the likelihood of a sale increases dramatically. In this latest announcement, Sanofi is seeking to choose a definite date for shareholders to have their say on the matter. Medivation responded with a statement indicating that the record date was set for 1 June.
According to the statement, the latest day the Medivation board could have set the record date is June 22, 2016. After the record date, Medivation directors can be removed and replaced at any time by shareholders delivering consents representing a majority of outstanding shares.
Medivation is said to be obligated to adopt a resolution fixing the record date within 10 calendar days of this request. Sanofi, it is clear, may know for sure whether they will successful in their bid to acquire Medivation sooner rather than later.
Sean Murray
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
